Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 13/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.60 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.48 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.48 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL859700 | 1.00 | HRH4 (0.72) | HRH4HRH3PRKD1PRKD2OGA | |
| SCHEMBL19233161 | 0.90 | HRH4 (0.67) | HRH4HRH3PRKD1PRKD2OGA | |
| SCHEMBL13574661 | 0.88 | HRH4 (0.80) | HRH4HRH3OGACXCR4 | |
| SCHEMBL1588697 | 0.84 | HRH4 (1.00) | HRH4HRH3OGACYP1A2HSD17B10 | |
| SCHEMBL13619336 | 0.83 | HRH4 (0.66) | HRH4HRH3CYP1A2HSD17B10CXCR4 | |
| Hydrochloric Acid SCHEMBL26599748 | 0.82 | HRH4 (0.64) | HRH4HRH3CYP1A2HSD17B10CXCR4 | |
| Hydrochloric Acid SCHEMBL30619112 | 0.82 | HRH4 (0.64) | HRH4HRH3CYP1A2HSD17B10CXCR4 | |
| SCHEMBL1588650 | 0.82 | HRH4 (1.00) | HRH4HRH3OGACXCR4 | |
| SCHEMBL8001807 | 0.80 | HRH4 (0.68) | HRH4HRH3OGACXCR4 | |
| SCHEMBL2575260 | 0.79 | HRH4 (0.71) | HRH4HRH3OGACXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | claimed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HRH4 2886/4885HRH3 2873/4885PRKD1 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.